Cardiff Oncology Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $108.00K Beat $40.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Cardiff Oncology (NASDAQ:CRDF) reported Q2 losses of $(0.25) per share, beating the analyst consensus estimate of $(0.27) by 7.41%. This is a 4.17% decrease over losses from the same period last year. The company also reported quarterly sales of $108.00K, beating the analyst consensus estimate of $40.00K by 170.00%, a 18.68% increase over sales from the same period last year.
August 09, 2023 | 9:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cardiff Oncology reported better than expected Q2 results with losses per share and sales beating analyst estimates. This could potentially have a positive impact on the company's stock.
Cardiff Oncology's Q2 results exceeded analyst expectations, with losses per share decreasing and sales increasing compared to the same period last year. This positive financial performance could potentially boost investor confidence and drive the company's stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100